Trial reportBlood2011
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Trial report in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.Leukemia research · 2016Trial
- Review
- Lenalidomide use in multiple myeloma (Review).Molecular and clinical oncology · 2024Review
- Effect of Lenalidomide on Pentylenetetrazole-Induced Clonic Seizure Threshold in Mice: A Role for N-Methyl-D-Aspartic Acid Receptor/Nitric Oxide Pathway.Journal of epilepsy research · 2021Article
- Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.Hematology, transfusion and cell therapy · 2019Article
- Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Pharmacotherapy of Myelofibrosis.Drugs · 2017Review
- Treatment of Myelofibrosis: Old and New Strategies.Clinical medicine insights. Blood disorders · 2017Review
- Myelofibrosis: an update on drug therapy in 2016.Expert opinion on pharmacotherapy · 2016Review
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.Cancer chemotherapy and pharmacology · 2016Review
- Novel therapies for myelofibrosis.Leukemia & lymphoma · 2015Review
- Novel myelofibrosis treatment strategies: potential partners for combination therapies.Leukemia · 2014Review
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.International journal of hematology · 2014Article
- Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.Journal of hematology & oncology · 2014Review
- Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.Chemical research in toxicology · 2014Article
- Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Leukemia & lymphoma · 2014Article
- JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.JAK-STAT · 2013Review
- Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.Wiener klinische Wochenschrift · 2013Observational
- Ruxolitinib for myelofibrosis.Experimental and therapeutic medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we re-assessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 received single-agent thalidomide, 41 single-agent lenalidomide, and 40 a combination of lenalidomide plus prednisone. The thalidomide group included significantly more untreated patients and patients with performance status of 2. The Lenalidomide-based therapy produced higher efficacy (34%-38%) than thalidomide (16%; P = .06). Responses to thalidomide were seen within 3-15 weeks, whereas responses to the lenalidomide-based therapy were also seen after a prolonged course of therapy (range, 2-45 weeks). Lenalidomide plus prednisone therapy resulted in significantly longer response duration (median, 34 months) than single-agent lenalidomide or thalidomide (median, 7 and 13 months, respectively; P = .042). Fewer patients (P = .001) discontinued the lenalidomide plus prednisone therapy (13%) because of side effects then patients on single-agents therapy (32%-39%). In conclusion, the combination of lenalidomide plus prednisone appears to be more effective and safer than single-agent thalidomide or lenalidomide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.